Pirtobrutinib

(Jayprica®)

Jayprica®

Drug updated on 1/4/2024

Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassKinase inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

Product Monograph / Prescribing Information

Document TitleYearSource
Jayprica (pirtobrutinib) Prescribing Information.2023Lilly USA, LLC, Indianapolis, IN

Randomized Controlled Trials